Yuki Kasahara

Sendai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Inverse Relation Between Responses to Pembrolizumab Plus Chemotherapy and Subsequent Cetuximab Plus Paclitaxel in Head and Neck Cancer: Role of the Janus Kinase-Signal Transducer and Activator of Transcription Signaling Pathway.

Inverse Relation Between Responses to Pembrolizumab Plus Chemotherapy and Subsequent Cetuximab Plus Paclitaxel in Head and Neck Cancer: Role of the Janus Kinase-Signal Transducer and Activator of Transcription Signaling Pathway.

Journal: JCO precision oncology

Published: April 23, 2026

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 31, 2026

Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations.

Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations.

Journal: Frontiers in oncology

Published: October 30, 2025

Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinoma.

Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinoma.

Journal: International journal of clinical oncology

Published: September 01, 2025

Attenuated Li-Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report.

Attenuated Li-Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report.

Journal: Familial cancer

Published: August 17, 2025

Plasma Lysophosphatidylcholine Levels Correlate with Prognosis and Immunotherapy Response in Squamous Cell Carcinoma.

Plasma Lysophosphatidylcholine Levels Correlate with Prognosis and Immunotherapy Response in Squamous Cell Carcinoma.

Journal: International journal of molecular sciences

Published: June 26, 2025

Outcomes of Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma: A Study Using Real-World Data.

Outcomes of Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma: A Study Using Real-World Data.

Journal: The Tohoku journal of experimental medicine

Published: February 12, 2025

Clinical utility of comprehensive genomic profiling tests using MTB management system at a single center in Japan.

Clinical utility of comprehensive genomic profiling tests using MTB management system at a single center in Japan.

Journal: Scientific reports

Published: November 22, 2024

Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database.

Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database.

Journal: International journal of clinical oncology

Published: September 28, 2024

A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phase.

A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phase.

Journal: Discover oncology

Published: August 09, 2024

Common progenitor origin for Rosai-Dorfman disease and clear cell sarcoma.

Common progenitor origin for Rosai-Dorfman disease and clear cell sarcoma.

Journal: The Journal of pathology

Published: May 28, 2024

Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.

Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.

Journal: International journal of colorectal disease

Published: May 26, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026